FDA Label for Budpak Feminine Anti-itch
View Indications, Usage & Precautions
Budpak Feminine Anti-itch Product Label
The following document was submitted to the FDA by the labeler of this product Budpak Inc.. The document includes published materials associated whith this product with the essential scientific information about this product as well as other prescribing information. Product labels may durg indications and usage, generic names, contraindications, active ingredients, strength dosage, routes of administration, appearance, warnings, inactive ingredients, etc.
Otc - Active Ingredient
Active Ingredients
Benzocaine 5%
Resorcinol 2%
Otc - Purpose
Purpose
External analgesic
Indications & Usage
Uses
- temporarily relieves itching
Warnings
Warnings
For external use only
Avoid contact with eyes
Otc - Stop Use
Stop use and ask a doctor if condition worsens or if symptoms worsens, or if symptoms persist for more than 7 days, or clear up and occur again within a few days.
Do not apply over large areas of the body.
Otc - Keep Out Of Reach Of Children
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away
Dosage & Administration
Directions
Adults and children, 2 years and older:
- Apply a fingertip amount (approximately 1-inch strip) to affected area not more than 3 to 4 times daily.
Children under 2 years of age: Consult a doctor
Other
Other information
- Store at room temperature 15°C to 30°C (59°F to 86°F).
- Lot No. Exp. Date: see crimp of the tube.
PRINCIPAL DISPLAY PANEL
Budpak Feminine Anti-Itch Cream
Benzocaine 5%
Resorcinol 2%
External analgesic
NET WT 0.75 OZ (21.2 g)
Inactive Ingredient
Inactive Ingredients
Purified water, cetyl alcohol, glyceryl stearate, PEG-100 stearate, mineral oil, isopropyl palmitate, aloe barbadensis leaf juice, alpha tocopherol acetate, corn oil, cholecalciferol, methyl paraben, isopropyl myristate, sodium sulfite, trolamine, trisodium HEDTA, vitamin A palmitate, carbomer homopolymer type c.
Package Label.Principal Display Panel
* Please review the disclaimer below.